CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “TRANSFORMATIVE ANTICANCER GENE THERAPY PLATFORM ADDRESSING A NOVEL THERAPEUTIC TARGET” at the Targeting Tumor Heterogeneity Conference organized by the New York Academy of Sciences May 8, 2019, in New York, New York.
Dr. Tetz’s presentation provided an overview of CLS-014, an engineered gene therapy platform addressing unmet need in pancreatic cancer with multiple follow-up extension opportunities. CLS-014 is an AAV vector that targets cell-free DNA, and has the potential for the treatment of solid tumors. The poster presentation also provided an overview of in vivo animal efficacy evaluating CLS-014 for the treatment of pancreatic cancer.
Poster Session Presentation Details:
- Title: Transformative Anticancer Gene Therapy Platform Addressing A Novel Therapeutic Target
- Poster Number: 26
- Event: Targeting Tumor Heterogeneity Conference (NYAS)
- Date: Wednesday, May 8, 2019
- Event Website: https://www.nyas.org/events/2019/targeting-tumor-heterogeneity/
About the CLS Therapeutics:
CLS Translating the new biology of cell-free DNA into novel therapeutic approaches for multiple cancers, beginning with our first program for pancreatic cancer. PC is the third-leading cause of cancer deaths in the United State with over 45,000 dying in 2018. It is expected to become the leading cause of cancer mortality already by 2030. 1-year survival is less than 30%. 5-year survival is less than 8%.
CLS-014 is in silico designed AAV-based AAV vector encoding hyperactive human DNase I transgene cassette. Intravenous injection of the vector with a liver specific promoter leads to long term increase of serum DNase I activity that cleaves cell-free DNA in the blood and therefore affecting primary tumor growth, metastasis and complications associated with NETosis.
CLS-014 is administered as a single injection with any first-line chemotherapeutic agents.
CLS-Therapeutics presented animal data demonstrating the efficacy of CLS-014 in the treatment of orthotopic pancreatic mouse xenograft model. CLS-014 alone, inhibited primary tumor growth and metastasis and potentiates nab-paclitaxel.
About CLS Therapeutics Inc.
CLS-Therapeutics Inc. is a preclinical-stage biopharmaceutical company focused to deliver on the promise of circulating nucleic acid science to advance a new generation of transformative gene therapies for cancer patients.
NEW YORK, April 1, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class -AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Frontiers in Cancer Immunotherapy” being held on May 14-15, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed) encoding DNase I of the treatment of pancreatic cancer animal model.
NEW YORK, NY / May 14, 2020 / CLS Therapeutics, a preclinical-stage anticancer gene therapy platform company developing novel medicines to bring the curative power of cell-free DNA destruction to patients with tumors, presented preclinical data on its AAV therapy clinical candidate, CLS-014, this week at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT).
NEW YORK, NY / April 06, 2021 / CLS Therapeutics, cancer gene therapy company utilizing a novel therapeutic target, announces presentation at the upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting.